Lyka Labs Limited (LYKALABS) Fair Value & Analysis
Healthcare · IN · Market cap ₹2.6B
Fair value as of: Jul 3, 2026
From 1 valuation models · updated today
Share price +24.2% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹44.95 – ₹116.18 · fair‑value band ₹12.78 – ₹25.56 · the ₹71.42 price screens above the ₹17.12 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Lyka Labs Limited (LYKALABS) currently trades at ₹71.42, while our model-based Fair Value estimate is ₹17.12 — implying the stock looks roughly 76.0% overvalued today. We read business quality at 33/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Lyka Labs Limited generated revenue of ₹1.3B at a net margin of -0.5%. Revenue declined 9.1% year over year. It earns a return on equity of 2.5%. Net debt stands at ₹475M. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant tablets and combination, proton pump inhibitor, nutraceuticals, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, anti-fungal and bacterial, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products. It also offers technical data, such as molecule stability testing data, impurity profile, and BA/BE clinical study data. The company offers its products in various forms, including injections, creams, ointments, foams, gels, and lotions. It also …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Lyka Labs Limited reported revenue of ₹1.3B in FY2026 versus ₹1.8B in FY2022, a compound −8.5%/yr. Reported net income was −₹100M in FY2026.
Is LYKALABS fairly valued? → Check now
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$574.00 | R$357.63 | -38% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $286.41 | $106.81 | -63% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Lyka Labs Limited (LYKALABS) undervalued?
What is the fair value of LYKALABS?
What is the quality score of LYKALABS?
What is the revenue of Lyka Labs Limited (LYKALABS)?
What is the net profit margin of LYKALABS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.